Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 20.13
- Piotroski Score 3.00
- Grade Buy
- Symbol (DMAC)
- Company DiaMedica Therapeutics Inc.
- Price $4.73
- Changes Percentage (13.16%)
- Change $0.55
- Day Low $4.17
- Day High $4.81
- Year High $4.95
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/17/2025
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $10.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.54
- Trailing P/E Ratio -4.74
- Forward P/E Ratio -4.74
- P/E Growth -4.74
- Net Income $-19,381,000
Income Statement
Quarterly
Annual
Latest News of DMAC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Replacing China in copper supply chain is 'unfeasible,' warns WoodMac, as the West seeks shift
China's dominance in the copper supply chain poses challenges for Western countries aiming to diversify. Wood Mackenzie warns that replacing China would require huge investments, leading to higher cos...
By CNBC | 3 months ago -
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 50% ownership, insiders own 39%
Individual investors hold significant control over DiaMedica Therapeutics, influencing management and governance decisions. Major shareholders include Thomas von Koch, Jan Stahlberg, and Richard Jacin...
By Yahoo! Finance | 4 months ago
